Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation.
about
Hepatitis B virus therapy: What's the future holding for us?Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionAntigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cellsVirus-like particles: a new family of delivery systems.Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain.Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses.Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.Revealing the potential of DNA-based vaccination: lessons learned from the hepatitis B virus surface antigen.Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 GMimovirus: a novel form of vaccine that induces hepatitis B virus-specific cytotoxic T-lymphocyte responses in vivoA polymeric protein induces specific cytotoxicity in a TLR4 dependent manner in the absence of adjuvants.Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.Tresperimus: a new agent for transplant tolerance induction.Heat-aggregated noninfectious influenza virus induces a more balanced CD8(+)-T-lymphocyte immunodominance hierarchy than infectious virusIntegrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics.Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte EpitopesDirect comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectorsHuman immunodeficiency virus (HIV) gag antigen-specific T-helper and granule-dependent CD8 T-cell activities in exposed but uninfected heterosexual partners of HIV type 1-infected individuals in North India.CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules.Multiple roles for CD4+ T cells in anti-tumor immune responses.Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like ParticlesDesign and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine.Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65MHC-I-restricted presentation of HIV-1 virion antigens without viral replication.Human immunodeficiency virus-like particles activate multiple types of immune cells.Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells.Eliciting unnatural immune responses by activating cryptic epitopes in viral antigens.
P2860
Q26774198-3476904A-07B3-466B-8673-42BE48794B8EQ26775082-6768897A-ACAE-4EC0-BB18-A59D4A2370ABQ28348352-238744A4-636C-4C78-A8B5-7E4572BA68A4Q30817169-B4BC0E44-CAC4-4718-B0F5-3FBA689A99B6Q33262483-C37FEFE9-8D69-4CA0-9E0B-62DED7863840Q33849973-F1934ACD-007A-40A9-911F-FF3080B5501BQ33916776-30270E7A-1B47-4639-8EF0-4713F6D834CEQ34280930-C9B6BCB7-4CE1-4896-BE2E-C4231A639CE8Q34342982-E7D36840-2424-4C6A-AF31-7E38B823FFCCQ34348477-02BEB756-53D2-46BB-862A-49CCE5DF2D4BQ34429859-42DB34ED-2B06-4238-8870-2FFCF380EA8EQ34437201-B8DDD405-992D-4626-9023-B10F2560B4B8Q34481608-CF0F3F3B-88C2-4D36-9C0F-E69772B9CC0CQ34858946-C03972BD-63EF-46C5-915C-CA2CD6E5C1BFQ35139200-285AF3E6-F29A-45F1-ABEC-8AFCEFBE8E74Q35635302-552F1DCA-17E9-49E8-8A1D-C961AE3469E2Q35827003-60FDAB95-78A3-45A1-B8F0-75C02609084EQ35914427-A7766EA9-0FE5-4164-ABB6-D021A362B340Q36095125-BF27969B-D85D-4E53-A984-7277318A4C4EQ36370281-E93F0F4E-4882-496D-AA0D-A6AA24AD4405Q37118150-C7EE31CF-9EF4-4A15-8787-0CC4222F3330Q37516075-290D9082-2CFE-4FEC-A8AD-971F6B7E7BD2Q39427650-8CB67BB0-9328-4F16-B296-1989DB964F58Q39606662-4ACC7C16-B247-440E-8F7E-8B846814ACA7Q40822849-1ACCB058-30D9-4E93-A75A-80045D9969F8Q42034526-1F2B0546-4A94-4D74-B795-1F935DCAE19BQ50747442-59BE5CFC-1788-4E45-826E-04CB9D286FA4Q52344693-D1704DCC-3EA9-4FC1-A1F3-83E245749247
P2860
Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Alternative pathways for proce ...... ass I-restricted presentation.
@ast
Alternative pathways for proce ...... ass I-restricted presentation.
@en
type
label
Alternative pathways for proce ...... ass I-restricted presentation.
@ast
Alternative pathways for proce ...... ass I-restricted presentation.
@en
prefLabel
Alternative pathways for proce ...... ass I-restricted presentation.
@ast
Alternative pathways for proce ...... ass I-restricted presentation.
@en
P2860
P1476
Alternative pathways for proce ...... ass I-restricted presentation.
@en
P2093
Schirmbeck R
P2860
P304
P356
10.1111/J.1600-065X.1999.TB01362.X
P577
1999-12-01T00:00:00Z